US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurosense Therapeutics Ltd

0.9963

+0.02092.14%

Volume:103.36K

Turnover:102.20K

Market Cap:23.90M

PE:-1.82

High:1.02

Open:1.02

Low:0.9600

Close:0.9754

Loading ...

Overview Company News Filings

Neurosense Therapeutics Announces Transformative Phase 2B Microrna Data, Highlighting Primec's Promise as a Disease-Modifying ALS Treatment

THOMSON REUTERS

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate

Press Release: NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)

NeuroSense Therapeutics Regains Compliance With Nasdaq Equity Requirement

MT Newswires Live

BRIEF-Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement

Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement

THOMSON REUTERS

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares

MT Newswires Live

NeuroSense files to sell 5.28M ordinary shares for holders

NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis

MT Newswires Live

NeuroSense enters binding term sheet to advance PrimeC for ALS

Neurosense Therapeutics Enters Binding Term Sheet to Advance Primec for ALS

THOMSON REUTERS

Neurosense Therapeutics Ltd: Co Would Retain Full Rights to Primec in Other Key Territories

THOMSON REUTERS

Press Release: NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NRSN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NRSN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRSN\",,,,,undefined,":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.9963,"timestamp":1745519470624,"preClose":0.9754,"halted":0,"volume":103364,"delay":0,"floatShares":11925112,"shares":23988669,"eps":-0.548863,"marketStatus":"Trading","change":0.0209,"latestTime":"04-24 14:31:52 EDT","open":1.02,"high":1.02,"low":0.96,"amount":102200.45212480001,"amplitude":0.061513,"askPrice":1.01,"askSize":1441,"bidPrice":0.9695,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.548863,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745524800000},"marketStatusCode":2,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.9754,"preHourTrading":{"tag":"盘前","latestPrice":1.0194,"preClose":0.9754,"latestTime":"09:27 EDT","volume":917,"amount":939.7407747000001,"timestamp":1745501247923},"postHourTrading":{"tag":"盘后","latestPrice":0.9999,"preClose":0.986947,"latestTime":"19:15 EDT","volume":1001,"amount":1000.8301,"timestamp":1745450144487},"volumeRatio":1.470476},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRSN\",,,,,undefined,":{"symbol":"NRSN","floatShares":11925112,"roa":"-159.50%","roe":"-2478.16%","lyrEps":-0.548863,"volumeRatio":1.470476,"shares":23988669,"dividePrice":0,"high":1.02,"amplitude":0.061513,"preClose":0.9754,"low":0.96,"week52Low":0.512,"pbRate":"9.25","week52High":1.5,"institutionHeld":0,"latestPrice":0.9963,"committee":-0.870214,"eps":-0.548863,"divideRate":0,"volume":103364,"delay":0,"ttmEps":-0.548863,"open":1.02,"prevYearClose":1.2,"prevWeekClose":1.0333,"prevMonthClose":0.9299,"prevQuarterClose":0.9299,"fiveDayClose":1.031,"twentyDayClose":1.0868,"sixtyDayClose":1.04},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NRSN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526936520","title":"Neurosense Therapeutics Announces Transformative Phase 2B Microrna Data, Highlighting Primec's Promise as a Disease-Modifying ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526936520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526936520?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN195:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2526366907","title":"NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2526366907","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526366907?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:30","pubTimestamp":1744201800,"startTime":"0","endTime":"0","summary":"New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.CAMBRIDGE, Mass., April 9, 2025 /PRNewswire/ --NeuroSense Therapeutics, Ltd. , a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new findings from its Phase 2b PARADIGM clinical trial. The data highlights the significant impact of PrimeC, the company's investigational therapy for the treatment of amyotrophic lateral sclerosis , on microRNA  modulation.Represent an important development in understanding how the therapy may slow disease progression in people living with ALS.This research, conducted in collaboration with Prof. Noam Shomron of Tel Aviv University's Facultyof Medical and Health Sciences, a leader in microRNA research and functional genomics, was presented yesterday by Jeffrey Rosenfeld, M.D., Ph.D., Professor of Neurology and Associate Chairman of Neurology at Loma Lind","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-announces-transformative-phase-123000446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4178","BK4139","NRSN","BK4007","AAN","NRSNW"],"gpt_icon":0},{"id":"2525107403","title":"NeuroSense Therapeutics FY 2024 GAAP EPS $(0.54) Beats $(0.60) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2525107403","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525107403?lang=en_us&edition=fundamental","pubTime":"2025-04-08 05:27","pubTimestamp":1744061226,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.60) by 10 percent. This is a 27.03 percent increase over losses of $(0.74) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44675520/neurosense-therapeutics-fy-2024-gaap-eps-0-54-beats-0-60-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","LENZ"],"gpt_icon":0},{"id":"2525137074","title":"Press Release: NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2525137074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525137074?lang=en_us&edition=fundamental","pubTime":"2025-04-08 05:14","pubTimestamp":1744060440,"startTime":"0","endTime":"0","summary":"-- Phase 2b study completed in amyotrophic lateral sclerosis . demonstrated lead asset PrimeC slows disease progression and functional. -- Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS. -- Phase 3 study design for PrimeC in ALS aligned with FDA; planned. Phase 2b study investigating PrimeC in ALS  with data showing the. -- Phase 3 study design for PrimeC for ALS aligned with FDA following Type C. \"2024 was a year of significant clinical progress for NeuroSense,\" stated NeuroSense CEO, Alon Ben-Noon. \"We successfully completed our Phase 2b study for PrimeC in ALS, with data showing transformative results in a neurodegenerative indication of immense medical need. The results conclude with PrimeC's disease-modifying potential and strongly support advancing PrimeC towards a Phase 3 study. With positive FDA feedback on the proposed study design, we are putting everything in place for the next stage of NeuroSense's growth, driven by PrimeC's continued clinical dev","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRSN","LENZ","BK4139"],"gpt_icon":0},{"id":"2524204220","title":"NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2524204220","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524204220?lang=en_us&edition=fundamental","pubTime":"2025-04-04 21:10","pubTimestamp":1743772200,"startTime":"0","endTime":"0","summary":"Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense. Jeremy Shefner, M.D., Ph.D., Chair of the Department of Neurology and Senior Vice President at the Barrow Neurological Institute, will present new, compelling data from the Phase 2b trial of PrimeC, NeuroSense's novel investigational therapy for amyotrophic lateral sclerosis , at 2:24 p.m. His presentation, \"Shifting the Paradigm: PrimeC, an Oral Candidate for ALS, Demonstrates Safety, Efficacy, and Target Engagement in an 18-Month Phase 2b Trial,\" will highlight PrimeC's disease-modifying potential in ALS treatment.\"This exciting Phase 2b trial data underscores PrimeC's potential to redefine ALS treatment,\" says Shefner. \"By demonstrating safety and tolerability, an indication of marked reduction in ALS progression, and multiple biomarker endpoints establishing PrimeC's biological activity, we move closer to offering a disease-modifying therapy t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-therapeutics-present-data-primecs-131000174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4178","NRSNW","AAN","BK4117","LENZ","BK4107","BK4139","NRSN"],"gpt_icon":0},{"id":"2520246811","title":"Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2520246811","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520246811?lang=en_us&edition=fundamental","pubTime":"2025-03-20 22:30","pubTimestamp":1742481000,"startTime":"0","endTime":"0","summary":"NeuroSense's Groundbreaking ALS Combination Therapy PrimeC Advances Towards commercialization in Canada; Potential for revenue in Canada alone of $100-150 million dollars. PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representing a Significant Premium Over Current Prices;NeuroSense is targeting potential approval in Canada by H1 2026. The company estimates peak annual revenue potential of $100-150M USD in the Canadian market. This meeting marks a critical step in NeuroSense's regulatory strategy for PrimeC. PrimeC is NeuroSense's lead drug candidate for ALS, a novel extended-release oral formulation combining ciprofloxacin and celecoxib. The drug has demonstrated promising results in clinical trials, including the Phase 2b PARADIGM study, which showed a 36% reduction in disease progression and 43% improvement in survival rates compared to placebo.Wall Street Analysts report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/market-alert-neurosense-therapeutics-advances-143000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRSN","NRSNW","BK4139","LENZ"],"gpt_icon":0},{"id":"2520361522","title":"PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2520361522","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520361522?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:30","pubTimestamp":1742214600,"startTime":"0","endTime":"0","summary":"NeuroSense's Breakthrough ALS Combination Therapy PrimeC Has Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representing a Significant Premium Over Current Prices; Recently Announced Binding Pharma Partnership Term Sheet Signals Potential for Hundreds of Millions of Dollars in Licensing for the Neurodegenerative Disease Market which is Experiencing Significant Growth. NEW YORK, March 17, 2025----PESG Research releases a new report covering NeuroSense Therapeutics * and its recent developments: In a medical landscape hungry for innovation, NeuroSense Therapeutics  stands at the forefront of a potential revolution in ALS treatment, developing a groundbreaking combination therapy that could fundamentally transform the approach to one of the most devastating neurological disorders. With clinical data showing a remarkable 36% reduction in disease progression and a 43% improvement in survival rates, the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pesg-releases-report-neurosense-therapeutics-123000478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NRSN","LENZ","NRSNW","BK4139"],"gpt_icon":0},{"id":"2508516094","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Elevance Health (ELV) and Genmab (GMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508516094","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508516094?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:40","pubTimestamp":1738676417,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurosense Therapeutics Ltd. (NRSN – Research Report), Elevance H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neurosense-therapeutics-ltd-nrsn-elevance-health-elv-and-genmab-gmab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-neurosense-therapeutics-ltd-nrsn-elevance-health-elv-and-genmab-gmab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELV","BK4139","LU1489326972.SGD","LU2362540622.SGD","LU0114720955.EUR","LU1720051108.HKD","LU0170899867.USD","SGXZ23171101.USD","LU0208291251.USD","LU2237957902.USD","BK4137","GMAB","LU0345770308.USD","LU0345770993.USD","LU0882574055.USD","LU0187121727.USD","LU0985489474.SGD","LU2362541513.USD","LU0266013472.USD","LU2244417387.USD","LU0320765489.SGD","SG9999011175.SGD","LU1057294990.SGD","LU1670628061.USD","SG9999001077.SGD","LU2505996681.GBP","SG9999003800.SGD","NRSN","LU0640476718.USD","LU1983299246.USD","LU0061474960.USD","LU0234570918.USD","LU0122379950.USD","LU0048573561.USD","LU0314106906.USD","LU2108987350.USD","LU0211331839.USD","HCSG","LU0225283273.USD","LU2505996509.AUD","LU2362541273.HKD","LU0433182093.SGD","LU0251142724.SGD","LU0957791311.USD","LU2357305700.SGD","LU2430703095.HKD","LU0070302665.USD","LU0251131958.USD","LU2237957811.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2501250950","title":"NeuroSense Therapeutics Regains Compliance With Nasdaq Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2501250950","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501250950?lang=en_us&edition=fundamental","pubTime":"2025-01-07 01:24","pubTimestamp":1736184273,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics  said Monday it received a written notice from Nasdaq that the company had regained compliance with the $2.5 million minimum stockholders' equity requirement.The company said it closed a $5 million financing in December.Shares of NeuroSense were up nearly 4.2% in recent trading.Price: 1.24, Change: +0.05, Percent Change: +4.20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","BK4215","IE00BKPKM429.USD","NQmain","EQR","BK4112","LU2095319765.USD","LU2210150020.SGD","BK4588","IE00B64PRP62.GBP","BK4139","LENZ","IE00BGHQF748.EUR","NRSN",".IXIC"],"gpt_icon":0},{"id":"2501523208","title":"BRIEF-Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2501523208","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501523208?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:01","pubTimestamp":1736172089,"startTime":"0","endTime":"0","summary":"BRIEF-Neurosense Regains Compliance With Nasdaq's Minimum Equity RequirementJan 6 (Reuters) - Neurosense Therapeutics Ltd NRSN.O:NEUROSENSE REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM EQUITY REQUIREMENTSource text: nPnbzLxcyaFurther company coverage: NRSN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O102I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2501716232","title":"Neurosense Regains Compliance With Nasdaq's Minimum Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2501716232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501716232?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:00","pubTimestamp":1736172030,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250106:nFWN3O102I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2501723761","title":"NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2501723761","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501723761?lang=en_us&edition=fundamental","pubTime":"2025-01-06 22:00","pubTimestamp":1736172000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-stage clinical biotechnology company developing novel treatments forsevere neurodegenerative diseases, today announced that the Company received formal written notice from The Nasdaq Stock Market LLC  that the Company has regained compliance with Nasdaq's stockholders' equity requirement  set forth in Nasdaq Listing Rule 5550. The Company's Ordinary Shares will continue to be listed and trade on The Nasdaq Capital Market under the symbol \"NRSN\".This confirmation follows the Company's successful efforts to improve its balance sheet by raising new equity and reducing outstanding liabilities. As a result, NeuroSense shareholders' equity now exceeds Nasdaq's Equity Requirement of at least $2.5 million.Alon Ben-Noon, CEO of NeuroSense, said: \"Regaining Nasdaq compliance is a significant milestone that reflects our dedicated efforts to strengthen the Company's financial position and ensure continued growth.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/neurosense-regains-compliance-nasdaqs-minimum-140000545.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neurosense-regains-compliance-nasdaqs-minimum-140000545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","NRSN","NRSNW","TSYW.SI","BK4588","USJW.SI","BK4112","MNQmain","TQQQ","IE00B3QW5Z07.USD","QID","BK4215",".IXIC","NQmain","NDAQ","SQQQ","BK4585","QLD","LU2095319765.USD","LU2210150020.SGD","EQR","IE00BKPKM429.USD","PSQ","LU2210149790.SGD","USAW.SI","NVIW.SI"],"gpt_icon":1},{"id":"2494619815","title":"Neurosense Therapeutics Files for Resale of Up to 5.28 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2494619815","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494619815?lang=en_us&edition=fundamental","pubTime":"2024-12-27 06:30","pubTimestamp":1735252233,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics  filed a registration statement with the US Securities and Exchange Commission Thursday for the resale of up to 5.28 million shares by Rimon Gold Assets from time to time.The resale includes up to 3.5 million warrants for stock, up to 1.66 million prefunded warrants and other shares, Neurosense said Thursday in a regulatory filing.The company won't receive any proceeds from the secondary offering.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","NRSN"],"gpt_icon":0},{"id":"2494182928","title":"NeuroSense files to sell 5.28M ordinary shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2494182928","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494182928?lang=en_us&edition=fundamental","pubTime":"2024-12-27 05:55","pubTimestamp":1735250104,"startTime":"0","endTime":"0","summary":"16:51 EST NeuroSense (NRSN) files to sell 5.28M ordinary shares for holders Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-files-to-sell-5-28m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-files-to-sell-5-28m-ordinary-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2493766371","title":"NeuroSense Signs Term Sheet for Phase 3 PrimeC Trial in Amyotrophic Lateral Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2493766371","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493766371?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:44","pubTimestamp":1734965048,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics  said Monday it has signed a binding term sheet with an unnamed pharmaceutical company to further develop PrimeC as potential treatment for amyotrophic lateral sclerosis in some key markets.NeuroSense said it would keep full rights to PrimeC in other key territories.The term sheet includes a \"substantial\" upfront payment\" and funding for a phase 3 study as well as milestone payments and royalties on annual net sales, NeuroSense said.A definitive agreement is expected to be finalized in Q1 2025, the company added.NeuroSense's shares were down more than 16% in early trading Monday.Price: 1.13, Change: -0.23, Percent Change: -16.91","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NRSN"],"gpt_icon":0},{"id":"2493632627","title":"NeuroSense enters binding term sheet to advance PrimeC for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493632627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493632627?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:05","pubTimestamp":1734962721,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-enters-binding-term-sheet-to-advance-primec-for-als?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-enters-binding-term-sheet-to-advance-primec-for-als?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2493768477","title":"Neurosense Therapeutics Enters Binding Term Sheet to Advance Primec for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768477","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768477?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0A6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2493684447","title":"Neurosense Therapeutics Ltd: Co Would Retain Full Rights to Primec in Other Key Territories","url":"https://stock-news.laohu8.com/highlight/detail?id=2493684447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493684447?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NO0A6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"gpt_icon":0},{"id":"2493768260","title":"Press Release: NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2493768260","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493768260?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:00","pubTimestamp":1734962400,"startTime":"0","endTime":"0","summary":"-- Binding Term Sheet with a leading global pharmaceutical company includes. a substantial upfront payment and funding for the Phase 3 study. -- Additionally, milestone payments and double-digit royalties on annual net. -- The transaction is subject to finalization of a definitive agreement,CAMBRIDGE, Mass., Dec. 23, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis  in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories.The binding term sheet outlines substantial financial terms from the pharmaceutical company, including:. During the first 6 months of the trial, 45 participants were randomized to r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN","LENZ"],"gpt_icon":0},{"id":"2492139238","title":"Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2492139238","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492139238?lang=en_us&edition=fundamental","pubTime":"2024-12-19 01:28","pubTimestamp":1734542887,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics Ltd reports results for the quarter ended September 30 - Earnings SummaryNeurosense Therapeutics Ltd NRSN.OQ reported a quarterly adjusted loss of 11 cents per share for the qu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL8N3NJ1EX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NRSN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-07","symbol":"NRSN","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743998400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-12-18","symbol":"NRSN","fiscalQuarterEnding":"2024/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1734498000000,"reportTimeType":"pre","actualEps":-0.11},{"market":"US","date":"2024-06-24","symbol":"NRSN","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1719201600000,"reportTimeType":"pre","actualEps":-0.35},{"market":"US","date":"2024-04-05","symbol":"NRSN","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1712289600000,"reportTimeType":"pre","actualEps":-0.16},{"market":"US","date":"2023-11-28","symbol":"NRSN","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1701147600000,"reportTimeType":"pre","actualEps":0.1}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NRSN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NRSN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1734408000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NRSN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NRSN","date":"2025-04-23","current":-2.373022,"percent":0.358974,"low":-12.966568,"twenty":-3.471816,"median":-2.107553,"eighty":-1.389598,"high":-0.395084,"avg":-2.544273,"sd":1.73234,"marketCap":24228555},"quantilePoints":[{"date":"2021-12-10","current":-6.574093,"twenty":-10.190888,"median":-8.533367,"eighty":-7.593999,"marketCap":34566580},{"date":"2021-12-17","current":-6.369292,"twenty":-8.481481,"median":-7.033255,"eighty":-6.696973,"marketCap":33489739},{"date":"2021-12-23","current":-6.010892,"twenty":-7.839759,"median":-6.778893,"eighty":-6.385676,"marketCap":31605268},{"date":"2021-12-31","current":-5.03809,"twenty":-7.126398,"median":-6.420492,"eighty":-5.387602,"marketCap":26490276},{"date":"2022-01-07","current":-5.24289,"twenty":-6.939702,"median":-6.041612,"eighty":-5.268367,"marketCap":27567116},{"date":"2022-01-14","current":-5.632011,"twenty":-6.791181,"median":-5.652491,"eighty":-5.268367,"marketCap":29613113},{"date":"2022-01-21","current":-4.812809,"twenty":-6.737933,"median":-5.611531,"eighty":-5.166254,"marketCap":25305751},{"date":"2022-01-28","current":-3.829767,"twenty":-6.545421,"median":-5.509131,"eighty":-4.931594,"marketCap":20136917},{"date":"2022-02-04","current":-3.725547,"twenty":-6.426636,"median":-5.37601,"eighty":-4.251656,"marketCap":19588925},{"date":"2022-02-11","current":-3.663107,"twenty":-6.40206,"median":-5.24289,"eighty":-3.929516,"marketCap":19260619},{"date":"2022-02-18","current":-3.267658,"twenty":-6.303756,"median":-5.10977,"eighty":-3.725547,"marketCap":17181348},{"date":"2022-02-25","current":-3.14278,"twenty":-6.041612,"median":-5.01761,"eighty":-3.663107,"marketCap":16524736},{"date":"2022-03-04","current":-3.954491,"twenty":-6.010892,"median":-4.91521,"eighty":-3.683921,"marketCap":20792714},{"date":"2022-03-11","current":-2.934649,"twenty":-5.672971,"median":-4.706253,"eighty":-3.645447,"marketCap":15430382},{"date":"2022-03-18","current":-3.246845,"twenty":-5.652491,"median":-4.464649,"eighty":-3.267658,"marketCap":17071913},{"date":"2022-03-25","current":-8.783133,"twenty":-6.369292,"median":-4.706253,"eighty":-3.352784,"marketCap":46181713},{"date":"2022-04-01","current":-7.804917,"twenty":-6.778893,"median":-4.91521,"eighty":-3.579855,"marketCap":41038252},{"date":"2022-04-08","current":-5.89011,"twenty":-7.033255,"median":-5.04833,"eighty":-3.621481,"marketCap":30970201},{"date":"2022-04-14","current":-5.470413,"twenty":-6.846149,"median":-5.01761,"eighty":-3.640654,"marketCap":22105938},{"date":"2022-04-22","current":-6.4995,"twenty":-6.782989,"median":-5.16097,"eighty":-3.659575,"marketCap":26264481},{"date":"2022-04-29","current":-4.54965,"twenty":-6.615053,"median":-5.207035,"eighty":-3.663107,"marketCap":18385137},{"date":"2022-05-06","current":-4.197594,"twenty":-6.514419,"median":-5.05857,"eighty":-3.663107,"marketCap":16962477},{"date":"2022-05-13","current":-3.439319,"twenty":-6.444486,"median":-4.985732,"eighty":-3.653865,"marketCap":13898288},{"date":"2022-05-20","current":-4.073327,"twenty":-6.414348,"median":-4.894729,"eighty":-3.613156,"marketCap":16460316},{"date":"2022-05-27","current":-4.304438,"twenty":-6.377484,"median":-4.641324,"eighty":-3.640654,"marketCap":17394234},{"date":"2022-06-03","current":-3.629217,"twenty":-6.349925,"median":-4.548658,"eighty":-3.579438,"marketCap":16810535},{"date":"2022-06-10","current":-3.679623,"twenty":-6.207023,"median":-4.495488,"eighty":-3.604831,"marketCap":17044015},{"date":"2022-06-17","current":-4.183681,"twenty":-6.073112,"median":-4.437259,"eighty":-3.626123,"marketCap":19378811},{"date":"2022-06-24","current":-4.284493,"twenty":-6.029324,"median":-4.307067,"eighty":-3.635709,"marketCap":19845771},{"date":"2022-07-01","current":-8.316957,"twenty":-6.35638,"median":-4.441325,"eighty":-3.649036,"marketCap":38524143},{"date":"2022-07-08","current":-6.754377,"twenty":-6.429933,"median":-4.495488,"eighty":-3.65473,"marketCap":31286274},{"date":"2022-07-15","current":-5.191797,"twenty":-6.429933,"median":-4.548658,"eighty":-3.657397,"marketCap":24048404},{"date":"2022-07-22","current":-4.61213,"twenty":-6.423442,"median":-4.61213,"eighty":-3.663107,"marketCap":21363388},{"date":"2022-07-29","current":-4.712942,"twenty":-6.40206,"median":-4.762875,"eighty":-3.663107,"marketCap":21830348},{"date":"2022-08-05","current":-4.788551,"twenty":-6.362836,"median":-4.788551,"eighty":-3.66641,"marketCap":22180567},{"date":"2022-08-12","current":-5.368217,"twenty":-6.329755,"median":-4.80068,"eighty":-3.680483,"marketCap":24865583},{"date":"2022-08-19","current":-4.939768,"twenty":-6.265441,"median":-4.838957,"eighty":-3.683921,"marketCap":22881006},{"date":"2022-08-26","current":-5.04058,"twenty":-6.123516,"median":-4.892046,"eighty":-3.688102,"marketCap":23347966},{"date":"2022-09-02","current":-3.184552,"twenty":-6.104613,"median":-4.889362,"eighty":-3.680483,"marketCap":22881006},{"date":"2022-09-09","current":-3.265791,"twenty":-6.041612,"median":-4.838957,"eighty":-3.663107,"marketCap":23464705},{"date":"2022-09-16","current":-3.2008,"twenty":-6.023493,"median":-4.80068,"eighty":-3.629217,"marketCap":22997746},{"date":"2022-09-23","current":-2.599634,"twenty":-6.010892,"median":-4.738145,"eighty":-3.553609,"marketCap":18678372},{"date":"2022-09-30","current":-2.908341,"twenty":-5.930794,"median":-4.697946,"eighty":-3.4664,"marketCap":20896429},{"date":"2022-10-07","current":-2.745864,"twenty":-5.89011,"median":-4.61213,"eighty":-3.363277,"marketCap":19729031},{"date":"2022-10-14","current":-2.778359,"twenty":-5.822469,"median":-4.548658,"eighty":-3.298286,"marketCap":19962510},{"date":"2022-10-21","current":-2.518396,"twenty":-5.795388,"median":-4.495488,"eighty":-3.249543,"marketCap":18094673},{"date":"2022-10-28","current":-2.469653,"twenty":-5.741225,"median":-4.437259,"eighty":-3.184552,"marketCap":17744454},{"date":"2022-11-04","current":-2.420909,"twenty":-5.723606,"median":-4.304438,"eighty":-3.168304,"marketCap":17394234},{"date":"2022-11-11","current":-2.453405,"twenty":-5.672971,"median":-4.278838,"eighty":-3.11156,"marketCap":17627714},{"date":"2022-11-18","current":-3.005177,"twenty":-5.670652,"median":-4.198408,"eighty":-3.038323,"marketCap":21592198},{"date":"2022-11-25","current":-2.84335,"twenty":-5.656123,"median":-4.197594,"eighty":-2.986918,"marketCap":20429470},{"date":"2022-12-02","current":-2.117174,"twenty":-5.636107,"median":-4.157963,"eighty":-2.932864,"marketCap":19670661},{"date":"2022-12-09","current":-1.985243,"twenty":-5.599243,"median":-4.108073,"eighty":-2.912736,"marketCap":18444893},{"date":"2022-12-16","current":-1.758322,"twenty":-5.574667,"median":-4.076348,"eighty":-2.875845,"marketCap":16336571},{"date":"2022-12-23","current":-1.633428,"twenty":-5.521419,"median":-3.954491,"eighty":-2.820603,"marketCap":15176177},{"date":"2022-12-30","current":-1.532909,"twenty":-5.4859,"median":-3.928883,"eighty":-2.778359,"marketCap":14242259},{"date":"2023-01-06","current":-1.584048,"twenty":-5.469859,"median":-3.892052,"eighty":-2.752363,"marketCap":14717390},{"date":"2023-01-13","current":-1.696252,"twenty":-5.468686,"median":-3.836529,"eighty":-2.70362,"marketCap":15759877},{"date":"2023-01-20","current":-2.257227,"twenty":-5.456819,"median":-3.807103,"eighty":-2.664625,"marketCap":20971894},{"date":"2023-01-27","current":-2.143097,"twenty":-5.410473,"median":-3.730029,"eighty":-2.632,"marketCap":19911517},{"date":"2023-02-03","current":-2.067011,"twenty":-5.399028,"median":-3.715187,"eighty":-2.586636,"marketCap":19204599},{"date":"2023-02-10","current":-2.117735,"twenty":-5.363632,"median":-3.683921,"eighty":-2.56064,"marketCap":19675878},{"date":"2023-02-17","current":-2.472805,"twenty":-5.337817,"median":-3.663107,"eighty":-2.498898,"marketCap":22974827},{"date":"2023-02-24","current":-2.586934,"twenty":-5.307925,"median":-3.659538,"eighty":-2.469653,"marketCap":24035204},{"date":"2023-03-03","current":-2.181267,"twenty":-5.306583,"median":-3.645447,"eighty":-2.421072,"marketCap":20266154},{"date":"2023-03-10","current":-2.168459,"twenty":-5.292609,"median":-3.600668,"eighty":-2.384037,"marketCap":20147156},{"date":"2023-03-17","current":-2.29527,"twenty":-5.24289,"median":-3.553609,"eighty":-2.307663,"marketCap":21325353},{"date":"2023-03-24","current":-1.662583,"twenty":-5.226682,"median":-3.507022,"eighty":-2.269908,"marketCap":20516275},{"date":"2023-03-31","current":-1.643473,"twenty":-5.217,"median":-3.439319,"eighty":-2.231865,"marketCap":20280456},{"date":"2023-04-06","current":-1.624363,"twenty":-5.196838,"median":-3.395772,"eighty":-2.206503,"marketCap":20044637},{"date":"2023-04-14","current":-1.595698,"twenty":-5.188271,"median":-3.35543,"eighty":-2.181242,"marketCap":19690908},{"date":"2023-04-21","current":-1.834574,"twenty":-5.170753,"median":-3.298286,"eighty":-2.165923,"marketCap":22638648},{"date":"2023-04-28","current":-1.815464,"twenty":-5.162095,"median":-3.266725,"eighty":-2.132364,"marketCap":22402829},{"date":"2023-05-05","current":-1.663852,"twenty":-5.104983,"median":-3.246845,"eighty":-2.105764,"marketCap":20531935},{"date":"2023-05-12","current":-1.663852,"twenty":-5.090986,"median":-3.192676,"eighty":-2.067939,"marketCap":20531935},{"date":"2023-05-19","current":-1.635165,"twenty":-5.090986,"median":-3.184406,"eighty":-2.021262,"marketCap":20177936},{"date":"2023-05-26","current":-1.577791,"twenty":-5.070824,"median":-3.160181,"eighty":-1.98273,"marketCap":19469938},{"date":"2023-05-30","current":-1.529979,"twenty":-5.065783,"median":-3.152057,"eighty":-1.972678,"marketCap":18879940},{"date":"2023-06-09","current":-1.667747,"twenty":-5.05857,"median":-3.123684,"eighty":-1.940201,"marketCap":22537929},{"date":"2023-06-16","current":-1.606625,"twenty":-5.04058,"median":-3.08034,"eighty":-1.922419,"marketCap":21711931},{"date":"2023-06-23","current":-1.397065,"twenty":-5.04058,"median":-3.038323,"eighty":-1.882,"marketCap":18879940},{"date":"2023-06-30","current":-1.257359,"twenty":-5.04058,"median":-2.989579,"eighty":-1.815464,"marketCap":16991946},{"date":"2023-07-07","current":-1.340783,"twenty":-5.039584,"median":-2.976275,"eighty":-1.751128,"marketCap":18119348},{"date":"2023-07-14","current":-1.331068,"twenty":-5.029005,"median":-2.934649,"eighty":-1.709433,"marketCap":17988049},{"date":"2023-07-21","current":-1.388002,"twenty":-5.015377,"median":-2.924589,"eighty":-1.68025,"marketCap":18757465},{"date":"2023-07-28","current":-1.32057,"twenty":-5.008078,"median":-2.911088,"eighty":-1.663852,"marketCap":17846185},{"date":"2023-08-04","current":-1.02823,"twenty":-4.994348,"median":-2.893022,"eighty":-1.662583,"marketCap":13895502},{"date":"2023-08-11","current":-1.018149,"twenty":-4.983838,"median":-2.859598,"eighty":-1.65429,"marketCap":13759272},{"date":"2023-08-18","current":-0.785704,"twenty":-4.970589,"median":-2.827102,"eighty":-1.643975,"marketCap":11988276},{"date":"2023-08-25","current":-0.803651,"twenty":-4.964971,"median":-2.794607,"eighty":-1.64232,"marketCap":12262100},{"date":"2023-09-01","current":-0.839275,"twenty":-4.95489,"median":-2.778359,"eighty":-1.635165,"marketCap":12805659},{"date":"2023-09-08","current":-0.832936,"twenty":-4.939768,"median":-2.762111,"eighty":-1.633428,"marketCap":12708935},{"date":"2023-09-15","current":-0.76508,"twenty":-4.939768,"median":-2.737821,"eighty":-1.624363,"marketCap":11673584},{"date":"2023-09-22","current":-0.785526,"twenty":-4.939768,"median":-2.697121,"eighty":-1.608262,"marketCap":11985552},{"date":"2023-09-29","current":-0.669634,"twenty":-4.934856,"median":-2.664625,"eighty":-1.59597,"marketCap":10217281},{"date":"2023-10-06","current":-0.521511,"twenty":-4.911114,"median":-2.63213,"eighty":-1.584467,"marketCap":7957218},{"date":"2023-10-13","current":-0.508922,"twenty":-4.893656,"median":-2.599634,"eighty":-1.571801,"marketCap":7765133},{"date":"2023-10-20","current":-0.482315,"twenty":-4.889362,"median":-2.586934,"eighty":-1.557715,"marketCap":7359167},{"date":"2023-10-27","current":-0.420977,"twenty":-4.889362,"median":-2.583386,"eighty":-1.550731,"marketCap":6423264},{"date":"2023-11-03","current":-0.427673,"twenty":-4.859119,"median":-2.575182,"eighty":-1.529941,"marketCap":6525437},{"date":"2023-11-10","current":-0.473207,"twenty":-4.838957,"median":-2.534643,"eighty":-1.428226,"marketCap":7220198},{"date":"2023-11-17","current":-0.458923,"twenty":-4.823268,"median":-2.50621,"eighty":-1.39344,"marketCap":7002243},{"date":"2023-11-24","current":-0.573296,"twenty":-4.803106,"median":-2.471229,"eighty":-1.365256,"marketCap":8747355},{"date":"2023-12-01","current":-1.530812,"twenty":-4.788551,"median":-2.434888,"eighty":-1.354573,"marketCap":17573724},{"date":"2023-12-08","current":-0.947576,"twenty":-4.768389,"median":-2.421072,"eighty":-1.344766,"marketCap":10878169},{"date":"2023-12-15","current":-1.035548,"twenty":-4.728064,"median":-2.409536,"eighty":-1.33788,"marketCap":11888089},{"date":"2023-12-22","current":-0.924958,"twenty":-4.712942,"median":-2.352334,"eighty":-1.320883,"marketCap":10618514},{"date":"2023-12-29","current":-0.928529,"twenty":-4.712942,"median":-2.34536,"eighty":-1.310489,"marketCap":10659512},{"date":"2024-01-05","current":-0.929719,"twenty":-4.694947,"median":-2.307807,"eighty":-1.276215,"marketCap":10673178},{"date":"2024-01-12","current":-1.105068,"twenty":-4.65558,"median":-2.29527,"eighty":-1.218395,"marketCap":12686186},{"date":"2024-01-19","current":-1.130782,"twenty":-4.627252,"median":-2.269908,"eighty":-1.115354,"marketCap":12981373},{"date":"2024-01-26","current":-1.226134,"twenty":-4.607157,"median":-2.231865,"eighty":-1.134639,"marketCap":14076023},{"date":"2024-02-02","current":-1.541596,"twenty":-4.579679,"median":-2.219184,"eighty":-1.141376,"marketCap":17697524},{"date":"2024-02-09","current":-1.571357,"twenty":-4.548856,"median":-2.206503,"eighty":-1.166661,"marketCap":18039175},{"date":"2024-02-16","current":-1.583261,"twenty":-4.543502,"median":-2.181267,"eighty":-1.20534,"marketCap":18175835},{"date":"2024-02-23","current":-1.499931,"twenty":-4.528904,"median":-2.18114,"eighty":-1.210592,"marketCap":17219212},{"date":"2024-03-01","current":-2.107047,"twenty":-4.48932,"median":-2.162119,"eighty":-1.21423,"marketCap":24188894},{"date":"2024-03-08","current":-2.392748,"twenty":-4.459984,"median":-2.18114,"eighty":-1.214653,"marketCap":27468744},{"date":"2024-03-15","current":-1.654686,"twenty":-4.439699,"median":-2.162119,"eighty":-1.217027,"marketCap":18995798},{"date":"2024-03-22","current":-2.154663,"twenty":-4.408494,"median":-2.143097,"eighty":-1.221037,"marketCap":24735536},{"date":"2024-03-28","current":-2.05943,"twenty":-4.309696,"median":-2.142759,"eighty":-1.226134,"marketCap":23642252},{"date":"2024-04-05","current":-2.452269,"twenty":-4.304438,"median":-2.155221,"eighty":-1.239925,"marketCap":28152046},{"date":"2024-04-12","current":-2.323708,"twenty":-4.284493,"median":-2.154663,"eighty":-1.257359,"marketCap":26211430},{"date":"2024-04-19","current":-2.102403,"twenty":-4.278838,"median":-2.155221,"eighty":-1.270167,"marketCap":23715103},{"date":"2024-04-26","current":-1.936249,"twenty":-4.278838,"median":-2.143097,"eighty":-1.279703,"marketCap":21840892},{"date":"2024-05-03","current":-1.951616,"twenty":-4.234087,"median":-2.139758,"eighty":-1.280247,"marketCap":22014233},{"date":"2024-05-10","current":-1.803785,"twenty":-4.198408,"median":-2.130855,"eighty":-1.285655,"marketCap":20346698},{"date":"2024-05-17","current":-1.874781,"twenty":-4.197795,"median":-2.117455,"eighty":-1.309749,"marketCap":21147531},{"date":"2024-05-24","current":-1.789876,"twenty":-4.197594,"median":-2.10806,"eighty":-1.310489,"marketCap":20189806},{"date":"2024-05-31","current":-1.726947,"twenty":-4.186464,"median":-2.105942,"eighty":-1.311407,"marketCap":19479966},{"date":"2024-06-07","current":-1.822889,"twenty":-4.163519,"median":-2.098772,"eighty":-1.318783,"marketCap":20562186},{"date":"2024-06-14","current":-1.631006,"twenty":-4.15786,"median":-2.091146,"eighty":-1.321039,"marketCap":18397746},{"date":"2024-06-21","current":-1.439123,"twenty":-4.147779,"median":-2.079191,"eighty":-1.321352,"marketCap":16233305},{"date":"2024-06-28","current":-1.461647,"twenty":-4.13811,"median":-2.074553,"eighty":-1.321352,"marketCap":18397746},{"date":"2024-07-05","current":-1.891543,"twenty":-4.118154,"median":-2.071187,"eighty":-1.327182,"marketCap":23808847},{"date":"2024-07-12","current":-1.475976,"twenty":-4.103339,"median":-2.059598,"eighty":-1.33212,"marketCap":18578116},{"date":"2024-07-15","current":-1.447317,"twenty":-4.101761,"median":-2.059514,"eighty":-1.33247,"marketCap":18217376},{"date":"2024-08-02","current":-0.974431,"twenty":-4.100183,"median":-2.05943,"eighty":-1.331068,"marketCap":12265164},{"date":"2024-08-09","current":-0.899916,"twenty":-4.07937,"median":-2.045943,"eighty":-1.311636,"marketCap":11327239},{"date":"2024-08-16","current":-1.06041,"twenty":-4.073327,"median":-2.025676,"eighty":-1.280247,"marketCap":13347384},{"date":"2024-08-23","current":-1.279298,"twenty":-3.986661,"median":-2.00107,"eighty":-1.257359,"marketCap":16102521},{"date":"2024-08-30","current":-1.175655,"twenty":-3.954491,"median":-1.988004,"eighty":-1.251453,"marketCap":14797964},{"date":"2024-09-06","current":-1.469568,"twenty":-3.93622,"median":-1.985243,"eighty":-1.252691,"marketCap":18497455},{"date":"2024-09-13","current":-1.995519,"twenty":-3.929437,"median":-1.982351,"eighty":-1.255411,"marketCap":25117597},{"date":"2024-09-20","current":-2.088334,"twenty":-3.927201,"median":-1.988004,"eighty":-1.25709,"marketCap":26285858},{"date":"2024-09-27","current":-1.964581,"twenty":-3.898998,"median":-1.986624,"eighty":-1.267605,"marketCap":24728177},{"date":"2024-10-04","current":-2.424436,"twenty":-3.875294,"median":-1.988004,"eighty":-1.277472,"marketCap":23754627},{"date":"2024-10-11","current":-2.424436,"twenty":-3.847995,"median":-1.99449,"eighty":-1.279622,"marketCap":23754627},{"date":"2024-10-18","current":-2.185967,"twenty":-3.833116,"median":-1.995519,"eighty":-1.280138,"marketCap":21418106},{"date":"2024-10-25","current":-2.404564,"twenty":-3.829982,"median":-2.003739,"eighty":-1.283201,"marketCap":23559917},{"date":"2024-10-31","current":-2.583416,"twenty":-3.80257,"median":-2.017353,"eighty":-1.284969,"marketCap":25312307},{"date":"2024-11-08","current":-2.563543,"twenty":-3.761592,"median":-2.035308,"eighty":-1.300111,"marketCap":25117597},{"date":"2024-11-15","current":-2.583416,"twenty":-3.736561,"median":-2.053627,"eighty":-1.310193,"marketCap":25312307},{"date":"2024-11-22","current":-1.828263,"twenty":-3.72734,"median":-2.059186,"eighty":-1.311177,"marketCap":17913325},{"date":"2024-11-29","current":-1.947697,"twenty":-3.725547,"median":-2.043819,"eighty":-1.31521,"marketCap":19083532},{"date":"2024-12-06","current":-2.066733,"twenty":-3.717259,"median":-2.053627,"eighty":-1.320883,"marketCap":20249846},{"date":"2024-12-13","current":-1.848136,"twenty":-3.696464,"median":-2.043819,"eighty":-1.321352,"marketCap":18108035},{"date":"2024-12-20","current":-2.149266,"twenty":-3.683921,"median":-2.039563,"eighty":-1.325238,"marketCap":24922887},{"date":"2024-12-27","current":-2.169482,"twenty":-3.683061,"median":-2.053627,"eighty":-1.331419,"marketCap":25157314},{"date":"2025-01-03","current":-2.293458,"twenty":-3.679623,"median":-2.059514,"eighty":-1.332821,"marketCap":26594934},{"date":"2025-01-10","current":-2.22944,"twenty":-3.66641,"median":-2.066733,"eighty":-1.335319,"marketCap":25852588},{"date":"2025-01-17","current":-2.233628,"twenty":-3.663107,"median":-2.066733,"eighty":-1.339815,"marketCap":25901153},{"date":"2025-01-24","current":-2.253571,"twenty":-3.663107,"median":-2.067011,"eighty":-1.340783,"marketCap":26132413},{"date":"2025-01-31","current":-2.11397,"twenty":-3.658824,"median":-2.072865,"eighty":-1.340783,"marketCap":24513591},{"date":"2025-02-07","current":-2.357276,"twenty":-3.65504,"median":-2.074083,"eighty":-1.34088,"marketCap":27334967},{"date":"2025-02-14","current":-2.333344,"twenty":-3.649036,"median":-2.074377,"eighty":-1.346677,"marketCap":27057455},{"date":"2025-02-21","current":-2.193742,"twenty":-3.638955,"median":-2.079191,"eighty":-1.350624,"marketCap":25438633},{"date":"2025-02-28","current":-2.133913,"twenty":-3.626123,"median":-2.088334,"eighty":-1.354573,"marketCap":24744852},{"date":"2025-03-07","current":-2.309213,"twenty":-3.604831,"median":-2.091146,"eighty":-1.360215,"marketCap":26777630},{"date":"2025-03-14","current":-2.243568,"twenty":-3.579438,"median":-2.094026,"eighty":-1.360985,"marketCap":26016413},{"date":"2025-03-21","current":-2.1382,"twenty":-3.568731,"median":-2.103728,"eighty":-1.365256,"marketCap":24794571},{"date":"2025-03-28","current":-2.083313,"twenty":-3.543528,"median":-2.105942,"eighty":-1.37266,"marketCap":24158098},{"date":"2025-04-04","current":-1.897978,"twenty":-3.525269,"median":-2.098772,"eighty":-1.378473,"marketCap":22008957},{"date":"2025-04-11","current":-2.322998,"twenty":-3.50973,"median":-2.102403,"eighty":-1.383833,"marketCap":23717812},{"date":"2025-04-17","current":-2.422362,"twenty":-3.488065,"median":-2.105942,"eighty":-1.388401,"marketCap":24732317},{"date":"2025-04-23","current":-2.373022,"twenty":-3.471816,"median":-2.107553,"eighty":-1.389598,"marketCap":24228555}],"updateTime":1745493548632}}}